Extended use and tolerance

Scope and caveats

Long-term kratom use has been studied through observational surveys of self-reported users, regulatory abuse-potential analyses, and preclinical safety pharmacology. Controlled long-term clinical trials in humans remain limited. This page summarises what is established and where the evidence base is still developing.

All claims below reference primary sources listed at the bottom of the page. Where the evidence is observational rather than experimental, or limited to animal models, the text says so.

Use patterns from observational data

Garcia-Romeu et al. (2020) reported one of the larger observational datasets on kratom use, surveying approximately 2,800 self-identified users on dose, frequency, motivations, and self-reported effects. Daily or near-daily use was the most commonly reported frequency in this sample, with typical doses in the 4–8 g range and primary motivations clustered around pain management, mood, and energy. The authors framed the dataset as informing the policy discussion rather than establishing clinical conclusions.^[1]

Observational data of this kind has well-known limits: self-selected respondents, self-reported dosing, recall bias, and the absence of placebo control. The Garcia-Romeu dataset and others like it are most useful as a description of who uses kratom and how — not as evidence of efficacy or long-term safety.

Regulatory analysis of abuse potential

Henningfield et al. (2022) updated an earlier eight-factor analysis of kratom's abuse potential against the criteria used in U.S. controlled-substance scheduling decisions. With five additional years of research and post-marketing surveillance data, the 2022 update reaffirmed the earlier finding that the available evidence does not support Schedule I classification. The analysis covered actual and relative abuse potential, scientific evidence of pharmacological effect, the state of scientific knowledge, history and current pattern of use, scope and significance of abuse, risk to public health, psychic and physiological dependence liability, and whether the substance is an immediate precursor.^[2]

An independent eight-factor analysis prepared by the School of Pharmacy at Concordia University Wisconsin reached parallel conclusions; the analysis is summarised at the policy-page level under Resources / Policy.

Tolerance and dependence — what the evidence says

The evidence base on tolerance and dependence in long-term kratom users is mixed and developing. Self-report data from user surveys document that some long-term users describe a progression in dose over time and discontinuation difficulty, while others describe stable dosing and uneventful cessation. The same Garcia-Romeu dataset referenced above includes self-reports across this full range; it does not establish a single normative trajectory.^[1]

The 2022 eight-factor analysis includes a discussion of psychic and physiological dependence liability that is informative for clinicians: the regulatory framework recognises that dependence-like phenomena have been documented but concludes that the overall risk profile is distinct from full-agonist opioid drugs and does not warrant Schedule I status.^[2]

Preclinical safety: respiratory effects

Acute respiratory safety has been studied in controlled animal models. Henningfield et al. (2022) compared oral mitragynine to oxycodone in rats: oxycodone administration produced significant dose-related respiratory depression and lethality at higher doses, while mitragynine showed no significant respiratory depressant effects even at exposures well above typical human dose ranges. The authors attribute the contrast to mitragynine's partial μ-opioid receptor agonism, which lacks the substantial β-arrestin pathway activation associated with full-agonist respiratory depression.^[3]

This work is preclinical and addresses acute exposure rather than long-term use. It is widely cited in the regulatory discussion of kratom's safety profile relative to traditional opioid drugs but should not be read as a statement of human long-term safety.

Open questions

• ·Controlled long-term clinical trials in humans — particularly studies of cumulative exposure, organ-system effects across years of regular use, and mechanisms of tolerance development — remain rare in the published literature.
• ·Drug-drug interactions across the medications commonly co-administered by kratom users (analgesics, SSRIs, sleep medications, etc.) are characterised at the level of metabolic mechanism but not extensively at the level of clinical outcomes.
• ·The distinction between effects observed with whole-leaf or full-spectrum extract use versus effects with concentrated 7-hydroxymitragynine products. Most of the evidence summarised here addresses the former; the latter is a distinct product category with its own safety discussion. See 7-hydroxymitragynine.